(Q33598141)

28 July 2017

1 reference

title

Angiogenesis in urological malignancy: prognostic indicator and therapeutic target (English)

1 reference

28 July 2017

A Jones

1 reference

28 July 2017

C Fujiyama

series ordinal

1 reference

28 July 2017

publication date

1 March 1999

1 reference

28 July 2017

1 reference

28 July 2017

1 reference

28 July 2017

1 reference

28 July 2017

page(s)

535-55; quiz 555-6

1 reference

Vascular endothelial growth factor is essential for corpus luteum angiogenesis.

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

What Is the Evidence That Tumors Are Angiogenesis Dependent?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Angiogenesis in urological malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Advances in angiogenesis research: relevance to urological oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Tumor Growth and Neovascularization: An Experimental Model Using the Rabbit Cornea 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Intratumoral vascularity as a prognostic factor in cancers of the urogenital tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Vasculogenesis, angiogenesis, and growth factors: ephrins enter the fray at the border

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

The biology of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Block of AIDS-Kaposi's sarcoma (KS) cell growth, angiogenesis, and lesion formation in nude mice by antisense oligonucleotide targeting basic fibroblast growth factor. A novel strategy for the therapy of KS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Correlation of basic fibroblast growth factor expression levels with the degree of malignancy and vascularity in human gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Thymidine phosphorylase is angiogenic and promotes tumor growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Tumor angiogenesis is regulated by CXC chemokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Hyperplasia of lymphatic vessels in VEGF-C transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Role of tissue factor in embryonic blood vessel development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Role of integrins in angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

The urokinase-type plasminogen activator system in cancer metastasis: A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Endothelial Cell-Specific Expression of Tumor Necrosis Factor-αfrom the KDR or E-Selectin Promoters Following Retroviral Delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Microvessel density in renal cell carcinoma: Lack of prognostic significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Clinical significance of tumor angiogenesis in patients with localized renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Tumour suppression by the human von Hippel-Lindau gene product

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Increased serum levels of basic fibroblast growth factor in patients with renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Correlation between thymidine phosphorylase expression and prognosis in human renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Interferon alfa-2a therapy for life-threatening hemangiomas of infancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

EORTC phase II study of daily oral linomide in metastatic renal cell carcinoma patients with good prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Accumulation of nuclear p53 and tumor progression in bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Prognostic significance of angiogenesis in transitional cell carcinoma of the human urinary bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Expression of scatter factor in human bladder carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Effects of epidermal growth factor on the invasion activity of the bladder cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Interaction of vasculotropin/vascular endothelial cell growth factor with human umbilical vein endothelial cells: Binding, internalization, degradation, and biological effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Suramin prevents neovascularisation and tumour growth through blocking of basic fibroblast growth factor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

A structure-activity analysis of antagonism of the growth factor and angiogenic activity of basic fibroblast growth factor by suramin and related polyanions

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional cooperative trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Prostate-specific antigen. An important marker for prostate cancer treated by external beam radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Carcinoma of the prostate. Hormonal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Topography of neovascularity in human prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Endothelial cell proliferation activity in benign prostatic hyperplasia and prostate cancer: an in vitro model for assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Serum basic fibroblast growth factor in men with and without prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Expression of mRNA for epidermal growth factor, transforming growth factor-alpha and their receptor in human prostate tissue and cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Suramin, an active drug for prostate cancer: interim observations in a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Vascular endothelial growth factor B, a novel growth factor for endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

The widespread expression of angiogenin in different human cells suggests a biological function not only related to angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Stimulation and inhibition of angiogenesis by placental proliferin and proliferin-related protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Stimulation of angiogenesis by substance P and interleukin‐1 in the rat and its inhibition by NK1 or interleukin‐1 receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Administration of Pentosan Polysulfate to Patients With Human Immunodeficiency Virus-Associated Kaposi's Sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Angiogenesis antagonists: current clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Angiogenesis: role of calcium-mediated signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

New anti-angiogenesis agents: review of the clinical experience with carboxyamido-triazole (CAI), thalidomide, TNP-470 and interleukin-12

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Antitumor Activity of Combined Blockade of Epidermal Growth Factor Receptor and Protein Kinase A

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Association of ovarian Malignancy With Expression of Paltelet-Derived Endothelial Cell Growth Factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Interleukin-4 is a potent mitogen for capillary endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

Relation of neovascularisation to metastasis of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.1999.00018.X

10.1046/J.1464-410X.1999.00018.X

21 January 2018

Identifiers

DOI

1 reference

28 July 2017

1 reference